Ambu A/S announces that the chairman of the board of directors Jens Bager has informed the board of directors that after 9 years of service he resigned from the board of directors. Jens Bager will resign as of Ambu’s annual general meeting in December 2019. Ambu’s board of directors proposes that Lars Rasmussen is elected as new chairman of the board of directors at the annual general meeting. Lars Rasmussen is, among others, chairman of the board of directors of Coloplast A/S and H. Lundbeck A/S. Furthermore, the board of directors proposes that Britt Meelby Jensen, CEO of the Swedish medtech company Atos Medical AB, is elected as new member of the board of directors at Ambu’s annual general meeting. Lars Rasmussen was born in 1959 and has vast experience within the medtech industry through a long career in Coloplast A/S in which he acted as CEO for 10 years. Lars Rasmussen is chairman of the board of directors of Coloplast A/S and the pharmaceutical company H. Lundbeck A/S. Lars Rasmussen is also a member of the board of directors of the medtech company Demant A/S and holds further management level posts in Germination af 2008 ApS, ADO Holding af 26.02.2004 and a subsidiary of the latter. Britt Meelby Jensen (born 1973) has extensive experience in the life science industry from leading positions in Novo Nordisk A/S and as the former CEO of diagnostics company Dako A/S and biotech company Zealand Pharma A/S. Currently, Britt Meelby Jensen is the CEO of the medtech company Atos Medical AB and is member of the Board of Directors of the Hempel Foundation.
Ambu A/S is specialized in the design, production and marketing of medical supplies. Net sales break down by family of products as follows:
- single-use endoscopes (56.3%);
- emergency care and resuscitation devices (22.9%): mechanical ventilation devices (insufflators, laryngeal masks, facial masks and respiratory bags), secretion aspirators, immobilization devices, etc. In addition, the group sells dummies for first aid training centers;
- monitoring and diagnostic devices (20.8%): including electrodes used in the fields of cardiology, neurophysiology and first aid.
At the end of September 2023, Ambu A/S had four production sites located in China, Malaysia, the United States and Mexico.
Net sales are distributed geographically as follows: Denmark (1.2%), Europe (37.8%), the United States (49.5%), North America (1.3%) and other (10.2%).
AMBU A/S 
